Ser759

Site Information
yQRsKsLsPsLLGYQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4727426

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 )
Disease tissue studied:	breast cancer ( 1 , 4 , 5 ) , cervical cancer ( 10 ) , cervical adenocarcinoma ( 10 ) , leukemia ( 6 ) , acute myelogenous leukemia ( 6 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 )
Relevant cell line - cell type - tissue:	BT-549 (breast cell) ( 5 ) , Calu 6 (pulmonary) ( 5 ) , H2009 (pulmonary) ( 5 ) , H2077 (pulmonary) ( 5 ) , H2887 (pulmonary) ( 5 ) , H322M (pulmonary) ( 5 ) , HCC1359 (pulmonary) ( 5 ) , HCC1937 (breast cell) ( 5 ) , HCC366 (pulmonary) ( 5 ) , HCC4006 (pulmonary) ( 5 ) , HCC78 (pulmonary) ( 5 ) , HCC827 (pulmonary) ( 5 ) , HeLa S3 (cervical) ( 10 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 1 ) , HMLER ('stem, breast cancer') ( 1 ) , HOP62 (pulmonary) ( 5 ) , Jurkat (T lymphocyte) ( 2 , 7 , 8 , 9 , 11 , 12 ) , K562 (erythroid) ( 3 ) , KG-1 (myeloid) ( 6 ) , LCLC-103H (pulmonary) ( 5 ) , MCF-7 (breast cell) ( 5 ) , MDA-MB-231 (breast cell) ( 5 ) , NCI-H1395 (pulmonary) ( 5 ) , NCI-H1568 (pulmonary) ( 5 ) , NCI-H1648 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 5 ) , NCI-H322 (pulmonary) ( 5 ) , NCI-H647 (pulmonary) ( 5 ) , SKBr3 (breast cell) ( 4 )

Upstream Regulation
Treatments:	nocodazole ( 10 )

References
1	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
2	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
3	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
4	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
5	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
6	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
7	Mulhern D (2011) CST Curation Set: 12701; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
8	Mulhern D (2011) CST Curation Set: 12682; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
9	Mulhern D (2011) CST Curation Set: 12572; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
10	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
11	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
12	Stokes M (2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info